The Efficacy and Safety of S-ketamine in Elective Cesarean Section
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
During the past years, a large number of clinical trials have investigated the use of the
non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist racemic ketamine as an
adjunct to local anaesthetics, opioids, or other analgesic agents for the management and
prevention of postoperative pain. Actually racemic ketamine not only abolishes peripheral
afferent noxious stimulation, but can also prevent the central nociceptor sensitization.
S-ketamine, one of two enantiomers of racemic ketamine, has twice the analgesic potency of
the racemate. Moreover, S-ketamine shows smaller nervous system and less psychotropic effects
than racemic ketamine , which may make the drug more suitable for clinical use. Recently,
S-ketamine has been approved to treat refractory depression (TRD) and major depressive
disorder (MDD) by the FDA .S-ketamine may have greater clinical significance due to the high
rate of maternal depression. Therefore, we plan to explore whether clinical use of S-ketamine
can optimize anesthesia protocol and improve maternal prognosis.
Phase:
N/A
Details
Lead Sponsor:
Beijing Obstetrics and Gynecology Hospital
Collaborators:
Beijing Chaoyang District Maternal and Child Health Care Hospital Beijing Haidian Maternal and Child Health Hospital Changzhi Maternal and Child Health Hospital China Health Promotion Foundation Fourth Hospital of Shijiazhuang City Linfen Maternity&Child Healthcare Hospital Maternal and Child Health Hospital, Jiading District Obstetrics & Gynecology Hospital of Fudan University Tongzhou Maternal and Child Healthcare Hospital of Beijing